BOSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, announced today that it has entered into a ...

Vor Biopharma is initiated to "Hold" rating as topline phase 3 MG data for telitacicept is expected in H1 2027. Telitacicept demonstrated a best-in-disease MG-ADL reduction of -4.8 at week 24 and -7.5 ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

The challenges facing biotechs amid the ongoing financial fallout have resulted in the winding down of one US biotech, Vor Bio, and job losses at a clutch of other firms. Cambridge, ...

Abstract: I welcome you to the fourth issue of the IEEE Communications Surveys and Tutorials in 2021. This issue includes 23 papers covering different aspects of communication networks. In particular, ...

Vor Bio (NASDAQ: VOR) announced on Monday that it has entered into a securities purchase agreement to sell 13.87M shares of its common stock at a price of $10.81 per share in a private placement. The ...

This price reflects trading activity during the overnight session on the Blue Ocean ATS, available 8 PM to 4 AM ET, Sunday through Thursday, when regular markets are closed.

Visit a quote page and your recently viewed tickers will be displayed here.

Vor Biopharma, Inc. engages in developing cell therapies for treating cancer. It is a clinical-stage cell therapy company that combines a novel patient engineering approach with therapies to provide a ...